The multicenter and retrospective analysis revealed that the EPIMMUNE signature could predict the response to anti-PD-1 treatment in non-small-cell lung cancer (Seremet et al., 2016). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.